Antipsychotic use in pregnancy - What are the best treatment options?

被引:29
作者
Trixler, M [1 ]
Tenyi, T [1 ]
机构
[1] UNIV PECS, SCH MED, DEPT PSYCHIAT & MED PSYCHOL, PECS, HUNGARY
关键词
D O I
10.2165/00002018-199716060-00006
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Both the rapid emergence of new antipsychotic medications and the increasing fertility rate among women with psychotic disorders have contributed to the growing clinical importance of the treatment of pregnant women who have psychotic illnesses. The treatment of this patient population must always take into consideration the effect of that treatment on the fetus. With regard to the high risk of decompensation during pregnancy and postpartum, continuous antipsychotic medication is needed using the minimum effective dose. The use of high-potency agents appears to be preferable for first-line management, as there are few data regarding the use of atypical agents such as clozapine in pregnancy. Guidelines for treating pregnant women with psychoses vary little from those for nonpregnant patients. Clinicians must always carefully weigh up the risks and benefits for each patient on an individual basis.
引用
收藏
页码:403 / 410
页数:8
相关论文
共 67 条
[1]  
Altshuler LL, 1996, AM J PSYCHIAT, V153, P592
[2]  
*AM MED ASS, 1983, AMA DRUG EV, P31
[3]  
[Anonymous], REV CONT PHARMACOTHE
[4]  
[Anonymous], 1990, DRUGS PREGNANCY LACT
[5]   MATERNAL PSYCHOTROPIC MEDICATION AND NEONATAL BEHAVIOR [J].
AUERBACH, JG ;
HANS, SL ;
MARCUS, J ;
MAEIR, S .
NEUROTOXICOLOGY AND TERATOLOGY, 1992, 14 (06) :399-406
[6]  
AYD FJ, 1972, DIS NERV SYST, V33, P459
[7]  
BERGA SL, 1995, COMPREHENSIVE TXB PS, P1693
[8]  
BERNSTEIN JG, 1995, HDB DRUG THERAPY PSY, P397
[9]   PUERPERAL MENTAL DISORDERS IN MANIC-DEPRESSIVE FEMALES [J].
BRATFOS, O ;
HAUG, JO .
ACTA PSYCHIATRICA SCANDINAVICA, 1966, 42 (03) :285-285
[10]   SUBTLE BEHAVIORAL-CHANGES PRODUCED IN RAT PUPS BY IN UTERO EXPOSURE TO HALOPERIDOL [J].
CAGIANO, R ;
BARFIELD, RJ ;
WHITE, NR ;
PLEIM, ET ;
WEINSTEIN, M ;
CUOMO, V .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1988, 157 (01) :45-50